$6.82

0.07 (1.04%)

5/9/2008 4:00 PM

Exelixis, Inc. (EXEL)

CAPS Rating:

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other players to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating EXEL

Add Stock to Watchlist

What the Community Thinks

Total Players

1816 Outperforms

60 Underperforms

All-Stars

416 Outperforms

24 Underperforms

Wall Street

2 Outperforms

0 Underperforms

Players bullish on EXEL are also bullish on:

Players bearish on EXEL are also bearish on:

Ticker Tags

Small Cap (1922), Biotechnology (291), Optionable (32), Research Services (46)
Suggest a tag

Exelixis, Inc. At A Glance

Current Price:	$6.82
Last Trade Time:	5/9/2008 4:00 PM
Open:	$0.00
Previous Close:	$6.75
Daily Range:	$6.55 - $6.83
52-Week Range:	$4.81 - $12.77
Volume:	827,305
Market Cap:	$709.50M
P/E Ratio:	0.00
Compare Our Special Broker Offers!

Stock Trends

EXEL VS S&P 500 (SPY)

News & Discussion Boards

Other News Headlines for EXEL

Genentech Will Fund Exelixis Cancer Drug
3/14/2008 6:30:00 PM - AP
Movers Roundup: Imax, Agnico-Eagle Mines
3/14/2008 4:34:00 PM - AP
Sector Wrap: Biotechnology
3/14/2008 3:07:00 PM - AP
GlaxoSmithKline to Develop Exelixis Drug
12/14/2007 10:45:00 AM - AP

More Headlines...

Top Bull Pitch

Recs

11 Exelixis, Inc. (EXEL)

Avatar ResearchLover (95.00) Submitted: 3/12/08 12:11 PM

I am a molecular biologist and have been at presentations for mid/late stage compounds, such as PPAR ligands, that EXEL is developing. They have the expertise to develop successful compounds. And they are at a bargain basement price now. If you need a signal to enter, wait for insider buying, whi...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

1 Exelixis, Inc. (EXEL)

Avatar BRADYstocks (21.72) Submitted: 2/25/08 9:26 PM

This sector is a scary one! Fear, though, is a fools game. I don't expect this stock to move upwards in the very near future. The cash burn is, well, similar to that Texas A&M bonfire tradition.

Replies: 0 | Reply | Permalink

CAPS Players

Show Me:

Sort by:

picks per page. CHANGE

Results 1 - 5 of 321 : 1 2 3 4 5 Next » Jump to page:

Recs 2 (EXEL) PDTBiotech (< 20) Submitted: 5/08/08 1:58 AM : Start Price: $6.90 EXEL Score: -0.52 Exelixis (EXEL) develops drugs for the treatment of cancer and other proliferative diseases. I had been looking for a decent entry point, and today's 11.65% drop on their earnings release looks like a decent one. The drop is most likely due to the 1Q loss of -0.39 vs. last year's -0.25. Since this is a development-stage company with all of their clinical compounds in Phase I or II studies I don't think this is surprising, as they spend more money on R&D while they advance their compounds through the clinic. EXEL is developing drugs to a wide, and well-selected, number of oncogenic targets. They have a nice mix of compounds, and a well-thought-out pertnership mix. Here's a look at their pipeline, which I consider to be robust: XL647 - EGFR, Her2, and VEGFR inhibitor - in Phase II trials for Non-Small Cell Lung Cancer (NSCLC). Outlicensed to Symphony Evolution, Inc. Has shown good efficacy in Phase II trial (350mg on days 1-5 of a 14-day cycle), with 68% of patients showing clinical benefit. Plus: ~190,000 new patients per year in the US, and one of the worst survival rates of all cancers means the bar is low to get approval and there's a huge patient pool. Minus: everyone and their grandpa is developing inhibitors to these RTK's. XL880 - MET and VEGFR inhibitor - in Phase II for papillary renal cell carcinoma (PRCC) and gastric, head and neck cancers in collaboration with GSK. 79% of patients in the PRCC study have had tumor shrinkage, and they saw 5 partial responses (at leats 30% shrinkage) in the Phase I trial. XL184 - MET, RET, and VEGFR inhibitor - in Phase I for solid tumors for which there are no available therapies. GSK has opt-in agreement (not exercised yet). It's only Phase I, but they've seen some good responses, particularly in medullary thyroid cancer patients. Have not determined MTD yet. XL820 - KIT, VEGFR2, and PDGFR inhibitor - in Phase I trial for patients with advanced solid tumors; GSK has opt-in rights. MTD not determined yet, no reports of responses or lack thereof yet. XL844 - CHK1 and CHK2 inhibitor - in Phase I in combination with Gemcitabine (Gemzar - LLY) for solid tumors. GSK has opt-in rights. Novel approach - CHK1 and CHK2 are cell cycle checkpoint proteins which stop division following DNA damage. XL844 inhibits them so the cancer cells will continue to divide, making them susceptible to radiation and DNA damaging agents (Gemzar is a nucleoside analog). No trial data yet. XL281 - B-RAF, C-RAF inhibitor - in Phase I for advanced solid tumors, GSK has opt-in rights. No data yet, looks like they're steering it towards melanoma. XL228 - Bcr-Abl, IGF1R, and Src inhibitor - in Phase I for CML and ALL, GSK has opt-in rights. No data yet, presumably would have to outperform Gleevec or show activity in Gleevec-resistant tumors. XL518 - MEK inhibitor - Phase I for advanced solid tumors, in collaboration with Genentech. Still recruiting, looking like they'll go with melanoma or colorectal cancer. XL147 - PI3K inhibitor - Phase I for solid tumors, wholly owned by EXEL. No data yet. XL765 - PI3K and mTOR inhibitor - Phase I for solid tumors, no response data yet, wholly owned. XL019 - JAK2 inhibitor - Phase I for patients with myeloproliferative disorders (polycythemia vera, essential thrombocytosis, and idiopathic thrombocytosis), wholly owned by EXEL. Well tolerated, has shown activity in Phase I. Awesome target - STAT3 activation, downstream of JAK2, is common in many cancers, they could expand studies to look at many different diseases with this drug. Since their most advanced compounds are only in Phase II the very earliest I'd expect to see them generating revenue from sales/royalties would be at least 2011. For the next few years they'll most likely be trying to determine the best indications for each drug and focusing how they want to proceed with development. With 11 candidates to proven targets, they're in great position to get several to market if they can stay afloat, and their partnership structure looks like it will get them there. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (EXEL) kkconway (< 20)* Submitted: 5/07/08 2:46 PM : Start Price: $6.92 EXEL Score: -0.82 Large drug pipeline, and perennial fav of Dave Gardner at Fool Rule Breakers. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 1 (EXEL) Budsworth (73.10) Submitted: 4/26/08 6:27 AM : Start Price: $7.99 EXEL Score: -13.99 From all the recent chatter I've read, Exelis is in on some real good discoveries. May 15 there will be some announcements letting the rest of the world just how far they have come in their tumor blasting cancer drugs. Apparently, some larger pharmaceutical companies are pretty confident. A financial "shot -in-the-arm" has helped them move forward. This looks like a true bargain .I'm in. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (EXEL) Dapperatom (63.40) Submitted: 4/24/08 11:04 AM : Start Price: $7.64 EXEL Score: -11.79 I like the below $10 price and its potential for a good return. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (EXEL) Rediggles (32.68) Submitted: 4/21/08 2:54 PM : Start Price: $7.77 EXEL Score: -12.51 Biotech with a lot in the pipeline. Demographic trends show that biotechs will be the source of strong growth going forward. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
Results 1 - 5 of 321 : 1 2 3 4 5 Next » Jump to page:

Wall Street

Results 1 - 2 of 2

picks per page. CHANGE Expand All Pitches Collapse All Pitches

Top Pick	Player Name	Player Rating	Start Date	Call	Time Frame	Start Price	Stock Gain	S&P Gain	Score	Pitch
	TrackEveillard	84.84	12/31/07		NS	$8.63	-20.97%	-5.00%	-15.97
	TrackLazardCapit	< 20	09/14/07		NS	$10.44	-34.67%	-6.40%	-28.28

Results 1 - 2 of 2

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.